Chemotherapy Choice Can Be Aided By Assessing TDP Profile

MedicalResearch.com Interview with:

Ed Liu, M.D President and CEO The Jackson Laboratory (JAX)

Dr. Ed Liu

Ed Liu, M.D
President and CEO
The Jackson Laboratory (JAX)

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: A few years ago we and others identified a complex genomic instability profile commonly found in the genomes of breast, ovarian and endometrial carcinomas, which is characterized by hundreds of isolated head-to-tail duplications of DNA segments, called tandem duplications. We refer to this configuration as the tandem duplicator phenotype, or TDP.

In this study, we perform a meta-analysis of over 2,700 cancer genomes from over 30 different tumor types and provide a detailed description of six different types of TDP, distinguished by the presence of tandem duplications of different sizes. Collectively, these profiles are found in ~50% of breast, ovarian and endometrial carcinomas as well as 10-30% of adrenocortical, esophageal, stomach and lung adeno-carcinomas. We show that distinct genetic abnormalities associate with the distinct TDPs, clearly suggesting that distinct molecular mechanisms are driving TDP formation. In particular, we provide strong evidence of a casual relationship between joint abrogation of the BRCA1 and TP53 tumor suppressor genes and the emergence of a short-span (~11 Kb) TDP profile. We also observe a significant association between hyper-activation of the CCNE1 pathway and TDP with medium-span (~230 Kb) tandem duplications, and between mutation of the CDK12 gene and medium- and large-span TDP (coexisting 230 Kb and 1.7 Kb tandem duplications).

Importantly, we find that different forms of TDP result in the perturbation of alternative sets of cancer genes, with short-span TDP profiles leading to the loss of tumor suppressor genes via double transections, and larger-span TDP profiles resulting in the duplication (i.e. copy number gain) of oncogenes and gene regulatory elements, such as super-enhancers and disease-associated SNPs. 

MedicalResearch.com: What should readers take away from your report?

Response: The TDPs are common genomic instability profiles that originate following precise molecular deficiencies and have the potential to alter the activity of hundreds of genes in any given cancer genome. Given our improved understanding of the molecular drivers and of the recurrent genomic consequences of the tandem duplications emerging in the context of the TDP, assessing the TDP status of a tumor can inform about which drugs are more luckily to be effective in counteracting tumor growth.   

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Whereas we provide a strong validation of the role of BRCA1 and TP53 in inducing the short-span TDP profile, we still need to validate/establish the exact molecular underpinnings of the other TDP types. Also, follow-up research is focused on assessing the usefulness of TDP assessment as a predictive biomarker for therapy response in the clinical setting.

No disclosures 

Citations:

Understanding The Genesis And Oncogenic Consequences Of Tandem Duplicator Phenotypes In Human Cancers

http://www.abstractsonline.com/pp8/#!/4562/presentation/7194

 

 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.